CPG 10101 combination therapy for the treatment of hepatitis C: A phase IB open label randomized trial of CPG 10101 alone, with interferon, ribavirin, or interferon and ribavirin in the treatment of relapsedhepatitis C Virus (HCV) subjects.

Trial Profile

CPG 10101 combination therapy for the treatment of hepatitis C: A phase IB open label randomized trial of CPG 10101 alone, with interferon, ribavirin, or interferon and ribavirin in the treatment of relapsedhepatitis C Virus (HCV) subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2011

At a glance

  • Drugs CPG 10101 (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Oct 2008 Official title updated, based on information from ClinicalTrials.gov.
    • 15 Apr 2007 Interim results have been presented.
    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top